Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.
about
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.Hairy cell leukemia: A retrospective study on 11 patients in the Western of Iran.Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression
P2860
Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Cladribine and bendamustine ex ...... istant multiple myeloma cells.
@en
Cladribine and bendamustine ex ...... istant multiple myeloma cells.
@nl
type
label
Cladribine and bendamustine ex ...... istant multiple myeloma cells.
@en
Cladribine and bendamustine ex ...... istant multiple myeloma cells.
@nl
prefLabel
Cladribine and bendamustine ex ...... istant multiple myeloma cells.
@en
Cladribine and bendamustine ex ...... istant multiple myeloma cells.
@nl
P2093
P2860
P1476
Cladribine and bendamustine ex ...... sistant multiple myeloma cells
@en
P2093
Choon-Kee Lee
Chunji Gao
Jingcao Huang
Shuiliang Wang
P2860
P407
P577
2013-01-21T00:00:00Z